JE (Japanese Encephalitis) Vaccine Market
January 3, 2025

Global JE (Japanese Encephalitis) Vaccine Market Growth, Size & Outlook 2025-2034

The global Japanese encephalitis (JE) vaccine market was estimated to be valued at USD 215.15 million in 2024. It is anticipated to grow at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2034, reaching an estimated value of USD 348.34 million by 2034. JE is a viral infection transmitted through mosquito bites, particularly in Asia and parts of the Pacific. The demand for JE vaccines is expected to rise due to growing awareness about the disease, increased vaccination efforts, and the expanding need for preventative measures in endemic regions.

This blog post delves into the various aspects of the JE vaccine market, including market dynamics, trends, growth opportunities, and segmentation. We also explore the key players, their contributions, and the market’s response to COVID-19.

Get a Free Sample Report with a Table of Contents: https://www.expertmarketresearch.com/reports/japanese-encephalitis-vaccine-market/requestsample

JE (Japanese Encephalitis) Vaccine Market Overview

Japanese encephalitis is a serious viral disease transmitted by infected mosquitoes. It can cause inflammation in the brain, leading to severe neurological complications or even death. The disease is primarily found in rural and semi-urban areas in Asia, with an increasing number of cases reported in the South-East Asia and Western Pacific regions.

The JE vaccine market is driven by rising incidences of JE infection, especially in endemic areas, and the growing availability of effective vaccines. Increasing awareness, healthcare infrastructure improvements, and government initiatives for mass immunisation campaigns are also contributing factors that will boost the market’s growth. Additionally, advancements in vaccine technology, including the development of more effective and safer vaccines, are likely to support market expansion.

Read Full Report with Table of Contents: https://www.expertmarketresearch.com/reports/japanese-encephalitis-vaccine-market

JE (Japanese Encephalitis) Vaccine Market Dynamics

Market Drivers

  1. Increasing Prevalence of JE in Endemic Areas: JE continues to be a significant health concern in many parts of Asia. Countries such as India, China, Indonesia, and the Philippines report a high incidence of the disease, making the demand for vaccines essential. The growing prevalence of JE in both rural and urban areas is one of the primary drivers for the growth of the vaccine market.
  2. Rising Government Vaccination Campaigns: Governments in JE-endemic countries have implemented large-scale immunisation programs to reduce the incidence of the disease. These vaccination programs are increasingly funded by international organisations like the World Health Organization (WHO) and GAVI (Global Alliance for Vaccines and Immunization), contributing to higher vaccination rates and growing market demand.
  3. Awareness About Vaccine Safety and Efficacy: Increased awareness about the safety and efficacy of JE vaccines, coupled with successful vaccination campaigns in various countries, is driving the acceptance and uptake of JE vaccines. Public health campaigns are helping to educate populations about the importance of vaccination in preventing the spread of the disease.

Market Restraints

  1. High Vaccine Cost in Developing Countries: While JE vaccines are crucial in endemic regions, the cost of vaccination can be a barrier, particularly in lower-income countries where healthcare budgets are limited. Financial constraints can lead to slower vaccine adoption, despite the high demand.
  2. Limited Awareness in Rural Areas: Despite efforts to raise awareness, some remote areas still have limited knowledge about JE and its preventive measures. This hampers vaccination uptake and slows market growth in those regions.
  3. Supply Chain Challenges: Distribution of vaccines to remote and rural areas, where JE is most prevalent, is a logistical challenge. The lack of a well-established supply chain in some developing regions can delay vaccine access and impact overall market growth.

External JE (Japanese Encephalitis) Vaccine Market Trends

Advancements in Vaccine Technology

There is a growing trend towards improving the quality and efficacy of JE vaccines. Researchers are working on developing vaccines that provide longer protection with fewer doses. Recombinant vaccines and cell-culture-based production methods are expected to play a significant role in enhancing vaccine safety and reducing production costs.

Rising Travel-Related JE Cases

With increased international travel, JE cases among travellers to endemic regions have been rising. This has led to greater demand for vaccines among tourists, expatriates, and humanitarian workers. Travel clinics are increasingly recommending JE vaccination for people visiting endemic areas, which in turn contributes to market growth.

Collaborations Between Private and Public Sectors

Several partnerships between private vaccine manufacturers and public health organisations, such as the WHO and GAVI, have been established to increase vaccine accessibility in low- and middle-income countries. These collaborations often focus on subsidising vaccine costs and increasing awareness to ensure that vaccination reaches the highest-risk populations.

JE (Japanese Encephalitis) Vaccine Market Segmentation

The JE vaccine market can be segmented based on vaccine type, end-user, and region.

By Vaccine Type

  1. Inactivated Vaccines: Inactivated vaccines are among the most widely used for JE. They are prepared by killing the virus and are safe for use in both children and adults. They offer good protection and have a long history of use in countries with high JE incidence.
  2. Live Attenuated Vaccines: Live attenuated vaccines use a weakened form of the virus. They offer strong and lasting immunity but are generally avoided in immunocompromised patients. These vaccines are particularly effective in preventing JE in endemic regions.
  3. Recombinant Vaccines: Recombinant vaccines are a relatively new category and are being increasingly explored due to their safety and ability to produce a strong immune response. These vaccines are made by inserting the genes responsible for generating the protective immune response into yeast or bacterial cells.

By End-User

  1. Pediatric Segment: Vaccination of children is one of the key focus areas for JE vaccine manufacturers. Many countries have included JE vaccines in their childhood immunisation schedules, particularly in regions with a high incidence of the disease.
  2. Adult Segment: The adult segment includes individuals traveling to endemic regions, as well as workers in agricultural and healthcare settings who may be exposed to mosquitoes carrying the JE virus.
  3. Traveler Segment: With increasing travel, especially to Asian countries where JE is prevalent, there is growing demand for vaccination among travelers. The vaccination recommendation is particularly common among tourists and expatriates visiting high-risk areas.

By Region

  1. Asia Pacific: The Asia Pacific region dominates the JE vaccine market due to the high burden of JE cases in countries like India, China, and Indonesia. Governments in these countries, along with international organisations, have heavily invested in vaccination programs.
  2. Europe: Although JE is less common in Europe, travel-related cases contribute to demand for vaccination. Vaccines are recommended for travelers heading to endemic regions, increasing the need for vaccination services in travel clinics.
  3. Rest of the World: The market for JE vaccines is also growing in countries outside of the primary endemic regions, particularly as global travel increases.

JE (Japanese Encephalitis) Vaccine Market Growth

The global JE vaccine market is expected to witness robust growth over the forecast period. Key factors driving this growth include the rising prevalence of JE in endemic areas, particularly in Asia, and increasing efforts by governments and healthcare organisations to control the disease through vaccination. The market is also being driven by technological advancements in vaccine production, which are expected to lower production costs and improve vaccine availability.

Furthermore, the COVID-19 pandemic highlighted the importance of vaccination in preventing infectious diseases, making governments and international health organisations more committed to increasing vaccination coverage for JE.

Recent Developments in the JE (Japanese Encephalitis) Vaccine Market

  • Launch of New Vaccines: Companies like Bharat Biotech International Limited and Valneva SE have launched new vaccines for JE, which are expected to contribute to the growth of the market by offering higher efficacy and broader coverage.
  • Expanded Vaccination Campaigns: Several countries, particularly in Southeast Asia, have introduced expanded vaccination campaigns to combat the increasing burden of JE. These initiatives have led to increased vaccine uptake, further driving market growth.
  • Public-Private Partnerships: Collaborations between vaccine manufacturers and governments, such as the partnership between Sanofi and various health authorities, have played a critical role in increasing vaccine availability and affordability in endemic regions.

JE (Japanese Encephalitis) Vaccine Market Scope

The JE vaccine market has substantial growth potential, especially in regions where the disease remains a significant health concern. There is also potential for increased vaccine sales outside of endemic regions, driven by international travel and the need for preventive healthcare.

Government and healthcare organisations worldwide are focusing on expanding immunisation programs, thus expanding the market scope. With growing investment in public health infrastructure, there is a strong market potential for both established and new vaccine manufacturers.

COVID-19 Impact Analysis

The COVID-19 pandemic had a mixed impact on the JE vaccine market. On one hand, it disrupted vaccine distribution and manufacturing operations due to lockdowns and supply chain challenges. On the other hand, the pandemic underscored the importance of vaccination and preparedness against infectious diseases, prompting governments and international organisations to prioritise vaccine availability.

As the world recovers from the pandemic, the demand for JE vaccines is expected to rise significantly, particularly in areas that are in urgent need of immunisation programs.

Key Players in the JE Vaccine Market

  1. Valneva SE: Valneva is a leading player in the JE vaccine market, known for its innovative vaccine offerings. The company is focused on developing new-generation vaccines that offer enhanced protection and ease of use.
  2. Sanofi: Sanofi has been a key player in the vaccine market, including the JE vaccine segment. The company’s vaccine division has made significant strides in making JE vaccines more accessible globally, particularly in Asia.
  3. Bharat Biotech International Limited: Bharat Biotech is a prominent Indian vaccine manufacturer that has developed effective JE vaccines. The company’s vaccines are widely used in Asia and other regions with high rates of JE.

FAQs

  1. What is Japanese Encephalitis (JE)?
    JE is a viral infection caused by the Japanese encephalitis virus, transmitted primarily by mosquitoes. It affects the central nervous system and can result in severe neurological damage or death.
  2. Why is the JE vaccine important?
    The JE vaccine helps prevent the disease by providing immunity against the virus. It is crucial for individuals living in or traveling to regions where JE is endemic.
  3. Which countries are most affected by JE?
    JE is primarily found in Asia and parts of the Pacific, particularly in countries like India, China, Indonesia, and the Philippines.
  4. Who should get the JE vaccine?
    The JE vaccine is recommended for people living in endemic regions, travelers to these regions, and individuals at high risk, such as healthcare workers or agricultural workers.
  5. What is the future of the JE vaccine market?
    The market is expected to grow significantly over the next decade, driven by increasing prevalence, government vaccination programs, and advancements in vaccine technology.